BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...Squibb Co. (NYSE:BMY) acquired in 2014; and CytomX...
BioCentury | Oct 12, 2020
Management Tracks

Rivera joins Akili as CMO; plus moves at Polyneuron, Checkmate, CytomX, BIO, ProQR, Silence and OncoSec

...COO Karen Brennan has retired. Its existing executive team will assume her responsibilities.Cancer mAb developer CytomX Therapeutics Inc....
...of research and non-clinical development, will retire Dec. 1. He will remain a company adviser. CytomX...
BioCentury | Sep 18, 2020
Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

...therapies and bispecific compounds, said CEO Debanjan Ray. Ray was previously CFO and head of BD at CytomX Therapeutics Inc....
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...development. Previously, Humphrey was CMO and a member of the board at fellow cancer company CytomX Therapeutics Inc....
BioCentury | May 15, 2020
Product Development

May 14 ASCO Quick Takes: Alphamab rises on responses for pair of bispecific mAbs; plus ImmunoGen and CytomX

...pembrolizumab and with carboplatin. Solo partial response for CytomX Probody drug conjugate in solid tumors CytomX Therapeutics Inc....
...advanced solid tumors. The Probody-drug conjugate targeting TFRC resulted in stable disease in nine patients; CytomX...
...1 TFRC (TFR; CD71) - Transferrin receptor BioCentury Staff KN046 KN026 mirvetuximab soravtansine (IMGN853) ABBV-2029, CX-2029 American Society of Clinical Oncology ImmunoGen Inc. CytomX Therapeutics Inc. Alphamab...
BioCentury | Apr 4, 2020
Finance

Pandemic upends norms for public fund-raising in election year

...impressive data (see “Akero Reports Positive Phase IIa Data for NASH” ). Linimeier also named CytomX Therapeutics Inc....
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...NYSE:TMO) is acquiring Qiagen for $11.5 billion (see “FDA Expanding U.S. COVID-19 Test Capacity” ). CytomX Therapeutics Inc....
...of Alder BioPharmaceuticals Inc., which H. Lundbeck A/S (CSE:LUN) acquired in October (see “Astellas Becomes CytomX’s...
...retiring April 30. Reali was president and CEO of Clinical Innovations LLC. Robin Sawka, BioCentury Staff Qiagen N.V. CytomX Therapeutics Inc. Recursion...
BioCentury | Mar 24, 2020
Deals

With bispecifics deal, Astellas becomes CytomX’s first new partner since 2017

...By teaming with Astellas to develop bispecifics for immuno-oncology, CytomX has struck its first major partnership...
...royalties (see “CytomX, Amgen Probody Deal” ). Under a 2016 deal with AbbVie Inc. (NYSE:ABBV), CytomX...
...Deal” ) CytomX gained $1.60 (32%) to $6.53 on Tuesday. Even with the gains, however, CytomX’s...
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

...launched in October with a €12 million series A (see "Abalos' Arena" ). Oncology company CytomX Therapeutics Inc....
...was SVP of business development and VA/integrated healthcare systems at MDxHealth S.A. (Euronext:MDXH). BioCentury Staff Boston Pharmaceuticals Inc. CytomX Therapeutics Inc. BioMarin...
BioCentury | Jan 14, 2020
Company News

Treadwell emerges with two clinical cancer compounds, $27M seed from Tio

...with the company’s debut. An industry veteran, Humphrey’s previous roles include SVP and CMO at CytomX Therapeutics Inc....
Items per page:
1 - 10 of 90
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...Squibb Co. (NYSE:BMY) acquired in 2014; and CytomX...
BioCentury | Oct 12, 2020
Management Tracks

Rivera joins Akili as CMO; plus moves at Polyneuron, Checkmate, CytomX, BIO, ProQR, Silence and OncoSec

...COO Karen Brennan has retired. Its existing executive team will assume her responsibilities.Cancer mAb developer CytomX Therapeutics Inc....
...of research and non-clinical development, will retire Dec. 1. He will remain a company adviser. CytomX...
BioCentury | Sep 18, 2020
Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

...therapies and bispecific compounds, said CEO Debanjan Ray. Ray was previously CFO and head of BD at CytomX Therapeutics Inc....
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...development. Previously, Humphrey was CMO and a member of the board at fellow cancer company CytomX Therapeutics Inc....
BioCentury | May 15, 2020
Product Development

May 14 ASCO Quick Takes: Alphamab rises on responses for pair of bispecific mAbs; plus ImmunoGen and CytomX

...pembrolizumab and with carboplatin. Solo partial response for CytomX Probody drug conjugate in solid tumors CytomX Therapeutics Inc....
...advanced solid tumors. The Probody-drug conjugate targeting TFRC resulted in stable disease in nine patients; CytomX...
...1 TFRC (TFR; CD71) - Transferrin receptor BioCentury Staff KN046 KN026 mirvetuximab soravtansine (IMGN853) ABBV-2029, CX-2029 American Society of Clinical Oncology ImmunoGen Inc. CytomX Therapeutics Inc. Alphamab...
BioCentury | Apr 4, 2020
Finance

Pandemic upends norms for public fund-raising in election year

...impressive data (see “Akero Reports Positive Phase IIa Data for NASH” ). Linimeier also named CytomX Therapeutics Inc....
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...NYSE:TMO) is acquiring Qiagen for $11.5 billion (see “FDA Expanding U.S. COVID-19 Test Capacity” ). CytomX Therapeutics Inc....
...of Alder BioPharmaceuticals Inc., which H. Lundbeck A/S (CSE:LUN) acquired in October (see “Astellas Becomes CytomX’s...
...retiring April 30. Reali was president and CEO of Clinical Innovations LLC. Robin Sawka, BioCentury Staff Qiagen N.V. CytomX Therapeutics Inc. Recursion...
BioCentury | Mar 24, 2020
Deals

With bispecifics deal, Astellas becomes CytomX’s first new partner since 2017

...By teaming with Astellas to develop bispecifics for immuno-oncology, CytomX has struck its first major partnership...
...royalties (see “CytomX, Amgen Probody Deal” ). Under a 2016 deal with AbbVie Inc. (NYSE:ABBV), CytomX...
...Deal” ) CytomX gained $1.60 (32%) to $6.53 on Tuesday. Even with the gains, however, CytomX’s...
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

...launched in October with a €12 million series A (see "Abalos' Arena" ). Oncology company CytomX Therapeutics Inc....
...was SVP of business development and VA/integrated healthcare systems at MDxHealth S.A. (Euronext:MDXH). BioCentury Staff Boston Pharmaceuticals Inc. CytomX Therapeutics Inc. BioMarin...
BioCentury | Jan 14, 2020
Company News

Treadwell emerges with two clinical cancer compounds, $27M seed from Tio

...with the company’s debut. An industry veteran, Humphrey’s previous roles include SVP and CMO at CytomX Therapeutics Inc....
Items per page:
1 - 10 of 90